Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 110 articles: HTML format

Single Articles

October 2026
1. GUO Q, Chen X, Wu L, Ren C, et al
   AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies.
   Oncogene. 2026;45:4132-4148.
   PubMed     Abstract available
   
   
   September 2026
2. FERNANDEZ-CALERO T, Metivier R, Percevault F, Clusan L, et al
   Synonymous codon usage shapes ERalpha function through specialized translational programs during breast cancer progression.
   Oncogene. 2026 Sep 24. doi: 10.1038/s41388-026-03991.
   PubMed     Abstract available
   
   
   August 2026
3. HU M, Peng H, Qiu G, Liu S, et al
   Decitabine suppresses triple-negative breast cancer by disrupting DNMT1 liquid-liquid phase separation and synergizes with G9a inhibition.
   Oncogene. 2026 Aug 26. doi: 10.1038/s41388-026-03971.
   PubMed     Abstract available
   
   
   
4. TANG C, Su K, Zhan Z, Huang R, et al
   Inhibition of PINK1/Parkin-mediated mitophagy enhances the susceptibility of breast cancer to cuproptosis.
   Oncogene. 2026 Aug 13. doi: 10.1038/s41388-026-03945.
   PubMed     Abstract available
   
   
   
5. DUAN Y, Alexandrou AT, Huang J, Zhang HS, et al
   Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression.
   Oncogene. 2026 Aug 12. doi: 10.1038/s41388-026-03941.
   PubMed     Abstract available
   
   
   
6. GONG C, Qu S, Liu B, Pan S, et al
   Correction to: MiR-106b expression determines the proliferation paradox of TGF-beta in breast cancer cells.
   Oncogene. 2026 Aug 10. doi: 10.1038/s41388-026-03954.
   PubMed    
   
   
   July 2026
7. MORINAGA T, Hayama S, Nakamura Y, Kawase K, et al
   A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis.
   Oncogene. 2026 Jul 10. doi: 10.1038/s41388-026-03894.
   PubMed     Abstract available
   
   
   
8. YI Y, Wang C, Yu X
   Repositioning osteocytes as integrative regulators of breast cancer bone metastasis.
   Oncogene. 2026 Jul 9. doi: 10.1038/s41388-026-03887.
   PubMed     Abstract available
   
   
   
9. SEIJO-VILA M, Balsinde SA, Blasco-Benito S, Tundidor I, et al
   Cannabinoid CB(2) receptor drives trastuzumab resistance and predicts durable anti-HER2 response.
   Oncogene. 2026;45:2436-2451.
   PubMed     Abstract available
   
   
   June 2026
10. YANG X, Su Y, Ying Y, Peng Y, et al
    DNA methylation-mediated silencing of STAT5A drives breast cancer metastasis via dual regulation of EMT and immunosuppressive microenvironment.
    Oncogene. 2026 Jun 29. doi: 10.1038/s41388-026-03849.
    PubMed     Abstract available
    
    
    
11. LI Q, Fan M, Sun X, Yang X, et al
    LCAL4-FUS cooperation switches on MMP13 and drives osteolytic bone metastasis in breast cancer.
    Oncogene. 2026 Jun 18. doi: 10.1038/s41388-026-03848.
    PubMed     Abstract available
    
    
    
12. YANG Q, Ding H, Chen L, Sun S, et al
    A feedback mechanism between E3 ligase RNF122 and HIF-1alpha inhibits aggressive behavior in breast cancer.
    Oncogene. 2026 Jun 17. doi: 10.1038/s41388-026-03853.
    PubMed     Abstract available
    
    
    
13. SUN Y, Feng R, Zhou X, Xu W, et al
    TIA1 depletion enhances CLSTN1 exon 11 inclusion to facilitate Epithelial-to-Mesenchymal transition and breast cancer metastasis.
    Oncogene. 2026 Jun 1. doi: 10.1038/s41388-026-03831.
    PubMed     Abstract available
    
    
    May 2026
14. CHEN B, Ma K, Zhong W, Wang Y, et al
    circPARPBP promotes cancer stemness and chemoresistance in triple-negative breast cancer through recruiting SRCAP complex to activate CCL20 transcription.
    Oncogene. 2026 May 21. doi: 10.1038/s41388-026-03819.
    PubMed     Abstract available
    
    
    
15. GHERGHELAS AM, Toseland CP
    ESR1 fusion proteins in breast cancer: distinguishing oncogenic drivers from passenger events.
    Oncogene. 2026 May 14. doi: 10.1038/s41388-026-03813.
    PubMed     Abstract available
    
    
    April 2026
16. SPELLECY O, Qadir J, Han R, Zhu K, et al
    Crosstalk between integrin signaling and NAD(+) biosynthetic pathways promotes glycolysis, proliferation, survival, and tumor growth in triple-negative breast cancer.
    Oncogene. 2026 Apr 29. doi: 10.1038/s41388-026-03780.
    PubMed     Abstract available
    
    
    
17. ZHANG Y
    Methodological considerations for centromere copy number analyses in HER2-positive metastatic breast cancer.
    Oncogene. 2026 Apr 16. doi: 10.1038/s41388-026-03793.
    PubMed    
    
    
    
18. HU H, Zhang H, Xing Y, Zhou Y, et al
    Correction: The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.
    Oncogene. 2026 Apr 15. doi: 10.1038/s41388-026-03790.
    PubMed    
    
    
    
19. LI S, Gong Y, Li H, Liu S, et al
    CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer.
    Oncogene. 2026 Apr 15. doi: 10.1038/s41388-026-03786.
    PubMed     Abstract available
    
    
    
20. LV X, Han L, Tong WW, Sun X, et al
    Blocking ubiquitination of hnRNPA1 maintains the self-renewal of breast cancer stem cells via mutually exclusive splicing of PKM pre-mRNA.
    Oncogene. 2026 Apr 14. doi: 10.1038/s41388-026-03776.
    PubMed     Abstract available
    
    
    
21. CHEN H, Hu X, Feng L, Cheng X, et al
    PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment.
    Oncogene. 2026 Apr 7. doi: 10.1038/s41388-026-03753.
    PubMed     Abstract available
    
    
    
22. GADAD SS, Camacho CV, Gong X, Thornton M, et al
    X-linked cancer-associated polypeptide (XCP) from lncRNA1456 modulates PHF8 histone demethylase activity to regulate the epigenome, gene expression, and cellular pathways in breast cancer.
    Oncogene. 2026 Apr 1. doi: 10.1038/s41388-026-03740.
    PubMed     Abstract available
    
    
    March 2026
23. WANG X, Li G, Wu J, Fu B, et al
    TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation.
    Oncogene. 2026 Mar 24. doi: 10.1038/s41388-026-03728.
    PubMed     Abstract available
    
    
    
24. ZHAO W, Wang G, Wang P, Ma B, et al
    Arginine methylation-dependent stabilization of SUV39H1 promotes breast cancer growth.
    Oncogene. 2026 Mar 7. doi: 10.1038/s41388-026-03712.
    PubMed     Abstract available
    
    
    
25. CHO B, Furlan G, Lin P, Shen M, et al
    CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer.
    Oncogene. 2026 Mar 7. doi: 10.1038/s41388-026-03709.
    PubMed     Abstract available
    
    
    February 2026
26. WILLIAMS AE, Hoffmann EJ, Inman DR, Gari MK, et al
    Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasis.
    Oncogene. 2026 Feb 28. doi: 10.1038/s41388-026-03718.
    PubMed     Abstract available
    
    
    
27. SZYMANSKI L, Schenk T, Lawinski M, Brioli A, et al
    Association of retinoids, retinoic acid receptors and epigenetics in breast cancer.
    Oncogene. 2026 Feb 20. doi: 10.1038/s41388-026-03699.
    PubMed     Abstract available
    
    
    
28. MA L, Sheng X, Wang L, Wan X, et al
    KDM6A alternative splicing induced by 25(OH)D inhibits breast cancer cell stemness through repressing TRAP1 transcription.
    Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03694.
    PubMed     Abstract available
    
    
    
29. DIAO H, Chen J, Zhang Y, Hua H, et al
    BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1(+) macrophage-mediated immune evasion in triple-negative breast cancer.
    Oncogene. 2026 Feb 14. doi: 10.1038/s41388-026-03681.
    PubMed     Abstract available
    
    
    January 2026
30. WU WY, Yang YS, Andriani L, Xie YF, et al
    TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.
    Oncogene. 2026 Jan 28. doi: 10.1038/s41388-025-03598.
    PubMed     Abstract available
    
    
    
31. DHAHRI H, Lau KH, Saintilnord WN, Lopes E, et al
    Single amino-acid differences define H2B variants and modify chromatin accessibility to induce EMT in breast cancer.
    Oncogene. 2026 Jan 24. doi: 10.1038/s41388-025-03636.
    PubMed     Abstract available
    
    
    
32. TAYA M, Fishman D, Kanani F, Zinger L, et al
    The role of the SLC25A15 transporter in the formation of liver metastasis in ESR1-mutated breast cancer.
    Oncogene. 2026 Jan 3. doi: 10.1038/s41388-025-03640.
    PubMed     Abstract available
    
    
    
33. WISNIEWSKI DJ, Voeller D, Addissie YA, Deshmukh SK, et al
    EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.
    Oncogene. 2026;45:15-25.
    PubMed     Abstract available
    
    
    December 2025
34. ANDRIEU C, Stoof J, AlSultan D, Ivers L, et al
    Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients.
    Oncogene. 2025 Dec 20. doi: 10.1038/s41388-025-03667.
    PubMed     Abstract available
    
    
    
35. DEY P, Bishnu A, Patel J, Mishra S, et al
    Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
    Oncogene. 2025 Dec 15. doi: 10.1038/s41388-025-03653.
    PubMed    
    
    
    November 2025
36. LI M, Xie W, Hu K, Li T, et al
    The novel endogenous micropeptide XLH-36 binds Gemin4 to promote triple-negative breast cancer metastasis.
    Oncogene. 2025 Nov 29. doi: 10.1038/s41388-025-03621.
    PubMed     Abstract available
    
    
    
37. REINHARDT J, Dankbar B, Geers F, Werbenko E, et al
    Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models.
    Oncogene. 2025 Nov 17. doi: 10.1038/s41388-025-03622.
    PubMed     Abstract available
    
    
    
38. ZHOU L, Liu M, Liu F, Wang Z, et al
    Circular RNA CLASP1 modulates the GLI1/SNAIL axis and enhances macrophage polarization in breast cancer.
    Oncogene. 2025 Nov 17. doi: 10.1038/s41388-025-03627.
    PubMed     Abstract available
    
    
    
39. CHEN S, Xiang L, He M, Han Q, et al
    Chaperone-mediated autophagy controlling VEGFR1 degradation contributes cross talk between breast cancer cells and endothelial cells triggering tumorigenesis via the VEGF-VEGFR2 axis.
    Oncogene. 2025 Nov 13. doi: 10.1038/s41388-025-03619.
    PubMed     Abstract available
    
    
    
40. MEDKOUR Y, Dufour CR, Han L, Hutton P, et al
    Regulation of ribosomal gene expression and senescence by a PML-mTOR-RONIN nuclear complex in triple-negative breast cancer.
    Oncogene. 2025 Nov 8. doi: 10.1038/s41388-025-03623.
    PubMed     Abstract available
    
    
    September 2025
41. CAI Y, Du J, Wang H, Shen L, et al
    KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.
    Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03503.
    PubMed     Abstract available
    
    
    
42. CHEN H, Zhou Y, Zhang Y, Fan Y, et al
    TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression.
    Oncogene. 2025 Sep 15. doi: 10.1038/s41388-025-03572.
    PubMed     Abstract available
    
    
    
43. DONG X, Dai H, Yao L, Lin Y, et al
    EMC2 promotes triple negative breast cancer growth by protecting FDFT1 from endoplasmic reticulum associated degradation to impair ferroptosis susceptibility.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03545.
    PubMed     Abstract available
    
    
    
44. UMBRICHT CB, Evron E, Gabrielson E, Ferguson AT, et al
    Correction: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
    Oncogene. 2025 Sep 5. doi: 10.1038/s41388-025-03555.
    PubMed    
    
    
    
45. TIAN L, Jiao X, Wang C, Li D, et al
    PPARgamma acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding.
    Oncogene. 2025;44:3476-3492.
    PubMed     Abstract available
    
    
    August 2025
46. CHEN X, Ma C, Li Y, Liang Y, et al
    Correction: COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2025 Aug 28. doi: 10.1038/s41388-025-03554.
    PubMed    
    
    
    
47. BARNIEH FM, Morton J, Olanrewaju O, El-Khamisy SF, et al
    Decoding the adaptive survival mechanisms of breast cancer dormancy.
    Oncogene. 2025 Aug 27. doi: 10.1038/s41388-025-03529.
    PubMed     Abstract available
    
    
    
48. MIYAN J, Kumar N, Moinuddin, Malik SA, et al
    Leveraging RAS-mSIN1 interaction to selectively inhibit mTORC2 employing competitive RAS binding peptide: implications in breast cancer metastasis.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03516.
    PubMed     Abstract available
    
    
    
49. HAWES ML, Moody MA, McCauley CR, Huddleston AG, et al
    Oncogenic effects of ECM remodeling in obesity and breast cancer.
    Oncogene. 2025 Aug 22. doi: 10.1038/s41388-025-03521.
    PubMed     Abstract available
    
    
    
50. GITHAKA JM, Kirschenman R, Patel N, Tripathi N, et al
    Multiple anti-tumor programs are activated by blocking BAD phosphorylation.
    Oncogene. 2025;44:2530-2546.
    PubMed     Abstract available
    
    
    
51. LIU J, Zhang S, Cao L, Zhang N, et al
    The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor.
    Oncogene. 2025;44:2515-2529.
    PubMed     Abstract available
    
    
    July 2025
52. GUO L, Rao Y, Song Y, Hu J, et al
    SIX1 transmits signals for breast cancer progression via the ZEB1/IL6/STAT3 signaling axis.
    Oncogene. 2025 Jul 26. doi: 10.1038/s41388-025-03499.
    PubMed     Abstract available
    
    
    
53. ZHAO Y, Qiao S, Hou X, Tian H, et al
    Correction: Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells.
    Oncogene. 2025 Jul 24. doi: 10.1038/s41388-025-03506.
    PubMed    
    
    
    
54. DURAN CL, Surve CR, Ye X, Chen X, et al
    Targeting CSF-1 signaling between tumor cells and macrophages at TMEM doorways inhibits breast cancer dissemination.
    Oncogene. 2025 Jul 11. doi: 10.1038/s41388-025-03485.
    PubMed     Abstract available
    
    
    
55. WU W, Wu W, Xie X, Li J, et al
    DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells.
    Oncogene. 2025;44:2283-2302.
    PubMed     Abstract available
    
    
    June 2025
56. LIU F, Liu W, Tan Y, Shang Y, et al
    PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.
    Oncogene. 2025 Jun 18. doi: 10.1038/s41388-025-03468.
    PubMed     Abstract available
    
    
    May 2025
57. ANAND V, El-Dana F, Baran N, Borgman J, et al
    GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function.
    Oncogene. 2025 May 17. doi: 10.1038/s41388-025-03432.
    PubMed     Abstract available
    
    
    April 2025
58. NING W, Yang J, Ni R, Yin Q, et al
    Correction: Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
    Oncogene. 2025 Apr 22. doi: 10.1038/s41388-025-03422.
    PubMed    
    
    
    
59. CHEN W, Jiang M, Zou X, Chen Z, et al
    Fibroblast Activation Protein (FAP)(+) cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin alpha5beta1 axis in breast cancer.
    Oncogene. 2025 Apr 22. doi: 10.1038/s41388-025-03359.
    PubMed     Abstract available
    
    
    
60. GAO Y, Li B, Jin Y, Cheng J, et al
    Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis.
    Oncogene. 2025 Apr 15. doi: 10.1038/s41388-025-03388.
    PubMed     Abstract available
    
    
    
61. CHEN S, Tang M, Yu X, Qian W, et al
    A microprotein encoded by LINC00263 promotes breast cancer osteolytic bone metastasis by inducing osteoclastogenesis and inhibiting osteoclast ferroptosis.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03400.
    PubMed     Abstract available
    
    
    
62. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
    Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03362.
    PubMed    
    
    
    
63. GUO Z, Dong RW, Wu Y, Dong S, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment.
    Oncogene. 2025 Apr 8. doi: 10.1038/s41388-025-03378.
    PubMed     Abstract available
    
    
    
64. MAN KF, Darweesh O, Hong J, Thompson A, et al
    Correction: CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Apr 2. doi: 10.1038/s41388-025-03369.
    PubMed    
    
    
    
65. HUANG J, Luo S, Shen J, Lee M, et al
    Cellular polarity pilots breast cancer progression and immunosuppression.
    Oncogene. 2025;44:783-793.
    PubMed     Abstract available
    
    
    
66. RANINGA PV, Zeng B, Moi D, Trethowan E, et al
    CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.
    Oncogene. 2025;44:893-908.
    PubMed     Abstract available
    
    
    
67. KIM K, Chadalapaka G, Lee S-, Yamada D, et al
    Editorial Expression of Concern: Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.
    Oncogene. 2025 Apr 1. doi: 10.1038/s41388-025-03363.
    PubMed    
    
    
    
68. JAIN A, Barge A, Parris CN
    Correction: Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
    Oncogene. 2025 Apr 1. doi: 10.1038/s41388-025-03364.
    PubMed    
    
    
    
69. MUGISHA S, Baba SA, Labhsetwar S, Dave D, et al
    S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers.
    Oncogene. 2025;44:1051-1062.
    PubMed     Abstract available
    
    
    March 2025
70. WANG H, Wang H, Wang R, Li Y, et al
    Discovery of a molecular glue for EGFR degradation.
    Oncogene. 2025;44:545-556.
    PubMed     Abstract available
    
    
    
71. ZHANG Z, Li F, Dai X, Deng J, et al
    A novel micropeptide miPEP205 suppresses the growth and metastasis of TNBC.
    Oncogene. 2025;44:513-529.
    PubMed     Abstract available
    
    
    
72. JI L, Chen J, He L, Zhang F, et al
    Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110alpha degradation.
    Oncogene. 2025;44:530-544.
    PubMed     Abstract available
    
    
    February 2025
73. WITKIEWICZ AK, Wang J, Schultz E, O'Connor TN, et al
    Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.
    Oncogene. 2025 Feb 26. doi: 10.1038/s41388-025-03308.
    PubMed     Abstract available
    
    
    
74. KONG Y, Lan T, Wang L, Gong C, et al
    Correction: BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2025 Feb 3. doi: 10.1038/s41388-024-03250.
    PubMed    
    
    
    
75. GAO ZX, Li CL, Zhang H, Zhang GH, et al
    LINC00882, transcriptionally activated by CEBP-beta and post-transcriptionally stabilized by METTL14-mediated m(6)A modification, exerts tumorigenesis by promoting PABPC1-mediated stabilization of ELK3 mRNA.
    Oncogene. 2025;44:363-377.
    PubMed     Abstract available
    
    
    January 2025
76. MAN KF, Darweesh O, Hong J, Thompson A, et al
    CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Jan 31. doi: 10.1038/s41388-025-03284.
    PubMed     Abstract available
    
    
    December 2024
77. GILLESPIE MS, Chiang K, Regan-Mochrie GL, Choi SY, et al
    PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells.
    Oncogene. 2024 Dec 18. doi: 10.1038/s41388-024-03264.
    PubMed     Abstract available
    
    
    
78. TANG T, Yang T, Xue H, Liu X, et al
    Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03237.
    PubMed     Abstract available
    
    
    November 2024
79. JAIN A, Barge A, Parris CN
    Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
    Oncogene. 2024 Nov 21. doi: 10.1038/s41388-024-03227.
    PubMed     Abstract available
    
    
    
80. ESCOTO A, Hecksel R, Parkinson C, Crane S, et al
    Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity.
    Oncogene. 2024 Nov 9. doi: 10.1038/s41388-024-03211.
    PubMed     Abstract available
    
    
    
81. NING W, Yang J, Ni R, Yin Q, et al
    Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
    Oncogene. 2024 Nov 4. doi: 10.1038/s41388-024-03213.
    PubMed     Abstract available
    
    
    September 2024
82. XIONG J, Zhou Z, Jiang Y, Li Q, et al
    Hypoxic stabilization of RIPOR3 mRNA via METTL3-mediated m(6)A methylation drives breast cancer progression and metastasis.
    Oncogene. 2024 Sep 28. doi: 10.1038/s41388-024-03180.
    PubMed     Abstract available
    
    
    
83. ZHANG C, Lu YJ, Wang M, Chen B, et al
    Characterisation of APOBEC3B-Mediated RNA editing in breast cancer cells reveals regulatory roles of NEAT1 and MALAT1 lncRNAs.
    Oncogene. 2024 Sep 25. doi: 10.1038/s41388-024-03171.
    PubMed     Abstract available
    
    
    
84. YOUSAFZAI NA, El Khalki L, Wang W, Szpendyk J, et al
    Kindlin-2 regulates the oncogenic activities of integrins and TGF-beta in triple-negative breast cancer progression and metastasis.
    Oncogene. 2024 Sep 19. doi: 10.1038/s41388-024-03166.
    PubMed     Abstract available
    
    
    
85. ZHAO G, Zhang X, Meng L, Dong K, et al
    Single-cell RNA-sequencing reveals a unique landscape of the tumor microenvironment in obesity-associated breast cancer.
    Oncogene. 2024 Sep 16. doi: 10.1038/s41388-024-03161.
    PubMed     Abstract available
    
    
    
86. FERNANDO W, Cruickshank BM, Arun RP, MacLean MR, et al
    ALDH1A3 is the switch that determines the balance of ALDH(+) and CD24(-)CD44(+) cancer stem cells, EMT-MET, and glucose metabolism in breast cancer.
    Oncogene. 2024 Sep 9. doi: 10.1038/s41388-024-03156.
    PubMed     Abstract available
    
    
    
87. GRASSET EM, Deshpande A, Lee JW, Cho Y, et al
    Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells.
    Oncogene. 2024;43:2927-2937.
    PubMed     Abstract available
    
    
    August 2024
88. KONG Y, Lan T, Wang L, Gong C, et al
    BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2024 Aug 20. doi: 10.1038/s41388-024-03121.
    PubMed     Abstract available
    
    
    
89. YU S, Wu R, Si Y, Fan Z, et al
    Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer.
    Oncogene. 2024 Aug 20. doi: 10.1038/s41388-024-03134.
    PubMed     Abstract available
    
    
    
90. CORBIN J, Yu X, Jin J, Cai L, et al
    EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03119.
    PubMed     Abstract available
    
    
    July 2024
91. LESLIE TK, Tripp A, James AD, Fraser SP, et al
    A novel Na(v)1.5-dependent feedback mechanism driving glycolytic acidification in breast cancer metastasis.
    Oncogene. 2024 Jul 25. doi: 10.1038/s41388-024-03098.
    PubMed     Abstract available
    
    
    
92. HAN X, Ren C, Lu C, Jiang A, et al
    Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC.
    Oncogene. 2024 Jul 5. doi: 10.1038/s41388-024-03097.
    PubMed     Abstract available
    
    
    June 2024
93. CASCIO S, Bartella V, Auriemma A, Johannes GJ, et al
    Retraction Note: Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha.
    Oncogene. 2024 Jun 20. doi: 10.1038/s41388-024-03087.
    PubMed    
    
    
    
94. SIRKISOON SR, Carpenter RL, Rimkus T, Anderson A, et al
    Correction: Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
    Oncogene. 2024 Jun 12. doi: 10.1038/s41388-024-03084.
    PubMed    
    
    
    
95. LEE SG, Woo SM, Seo SU, Lee HS, et al
    Non-canonical deubiquitination of OTUB1 induces IFNgamma-mediated cell cycle arrest via regulation of p27 stability.
    Oncogene. 2024;43:1852-1860.
    PubMed     Abstract available
    
    
    May 2024
96. DORE S, Ali M, Sorin M, McDowell SAC, et al
    Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
    Oncogene. 2024 May 14. doi: 10.1038/s41388-024-03051.
    PubMed     Abstract available
    
    
    
97. DAS C, Bhattacharya A, Adhikari S, Mondal A, et al
    A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
    Oncogene. 2024 May 8. doi: 10.1038/s41388-024-03054.
    PubMed     Abstract available
    
    
    
98. MA J, Chen Y, Li T, Cao Y, et al
    Suppression of lysosome metabolism-meditated GARP/TGF-beta1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.
    Oncogene. 2024 May 2. doi: 10.1038/s41388-024-03043.
    PubMed     Abstract available
    
    
    
99. LAISNE M, Rodgers B, Benlamara S, Wicinski J, et al
    A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors.
    Oncogene. 2024;43:1369-1385.
    PubMed     Abstract available
    
    
    April 2024
100. DOHENY D, Sirkisoon S, Carpenter RL, Aguayo NR, et al
     Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
     Oncogene. 2024 Apr 27. doi: 10.1038/s41388-024-03046.
     PubMed    
     
     
     
101. ZHOU Z, Zheng X, Zhao J, Yuan A, et al
     ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer.
     Oncogene. 2024 Apr 17. doi: 10.1038/s41388-024-03035.
     PubMed     Abstract available
     
     
     
102. CHEN X, Ma C, Li Y, Liang Y, et al
     COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
     Oncogene. 2024 Apr 12. doi: 10.1038/s41388-024-03030.
     PubMed     Abstract available
     
     
     
103. BOTTONI L, Minetti A, Realini G, Pio E, et al
     NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
     Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
     PubMed     Abstract available
     
     
     
104. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
     Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
     Oncogene. 2024 Apr 5. doi: 10.1038/s41388-024-03023.
     PubMed    
     
     
     March 2024
105. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
     E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
     Oncogene. 2024 Mar 20. doi: 10.1038/s41388-024-03007.
     PubMed     Abstract available
     
     
     
106. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
     Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
     Oncogene. 2024;43:1063-1074.
     PubMed     Abstract available
     
     
     February 2024
107. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
     Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
     Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02990.
     PubMed    
     
     
     
108. YANG L, Wang M, Wang Y, Zhu Y, et al
     LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
     Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02972.
     PubMed     Abstract available
     
     
     
109. ZHENG XQ, Guo JP, Yang H, Kanai M, et al
     Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer.
     Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02983.
     PubMed    
     
     
     
110. BARRA J, Crosbourne I, Roberge CL, Bossardi-Ramos R, et al
     DMT1-dependent endosome-mitochondria interactions regulate mitochondrial iron translocation and metastatic outgrowth.
     Oncogene. 2024;43:650-667.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum